| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 10,000 | $17.82 | $178,180.00 | -22.0% | |
| Aug 14, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 3,000 | $14.28 | $42,840.00 | - | |
| Aug 14, 2018 | PRGO Perrigo Co Plc | Andersen Svend47 | EVP &President Chci | Buy | 7,200 | $69.43 | $499,896.00 | New | |
| Aug 14, 2018 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | CAO And General Counsel | Sell | 4,773 | $47.04 | $224,521.92 | -17.6% | |
| Aug 14, 2018 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 36,318 | $55.98 | $2,033,109.26 | -1.2% | |
| Aug 13, 2018 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 7,215 | $2.42 | $17,476.60 | -0.1% | |
| Aug 13, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 6,429 | $14.32 | $92,032.67 | - | |
| Aug 10, 2018 | AVDL Avadel Pharmaceuticals Plc | Anderson Michael S | Chief Executive Officer | Sell | 16,297 | $4.91 | $79,953.08 | -6.1% | |
| Aug 10, 2018 | AVDL Avadel Pharmaceuticals Plc | Hatten Sandra L | See Remarks | Sell | 6,290 | $4.91 | $30,858.74 | -12.5% | |
| Aug 10, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 3,587 | $103.06 | $369,676.22 | - | |
| Aug 10, 2018 | HROW Harrow, Inc. | Kammer Robert J | Director | Sell | 130,000 | $3.00 | $390,000.00 | -12.3% | |
| Aug 9, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Codner Iris Beck | EVP Global Brand&Communication | Sell | 4,165 | $22.70 | $94,541.34 | -33.4% | |
| Aug 9, 2018 | BCRX Biocryst Pharmaceuticals Inc | Sheridan William P67 | Senior VP - CMO | Sell | 62,500 | $7.03 | $439,375.00 | -72.9% | |
| Aug 9, 2018 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 1,235 | $2.72 | $3,362.80 | - | |
| Aug 8, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 30,000 | $50.20 | $1,505,955.00 | -51.3% | |
| Aug 8, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 30,000 | $50.20 | $1,505,955.00 | -51.3% | |
| Aug 7, 2018 | TLPH Talphera, Inc. | Edwards Mark G | Director | Buy | 5,300 | $2.84 | $15,062.60 | +3.4% | |
| Aug 7, 2018 | TLPH Talphera, Inc. | Angotti Vincent J.56 | Chief Executive Officer | Buy | 10,000 | $2.90 | $28,950.00 | +40.0% | |
| Aug 7, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 24,620 | $103.22 | $2,541,325.64 | - | |
| Aug 7, 2018 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 4,681 | $3.00 | $14,049.67 | - | |
| Aug 6, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 195,000 | $102.15 | $19,918,860.00 | -0.2% | |
| Aug 6, 2018 | TLPH Talphera, Inc. | Palmer Pamela P | Chief Medical Officer | Buy | 37,000 | $2.75 | $101,750.00 | +8.8% | |
| Aug 6, 2018 | TLPH Talphera, Inc. | Asadorian Raffi | Chief Financial Officer | Buy | 5,000 | $2.75 | $13,725.00 | +18.5% | |
| Aug 3, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Buy | 2,000 | $21.92 | $43,840.00 | +45.0% | |
| Aug 3, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 1,650 | $13.55 | $22,357.50 | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.